ArticleThe oncologist2026
Association of IDH1 mutations with survival and recurrence in resected intrahepatic cholangiocarcinoma received or not received adjuvant chemotherapy.
Article in The oncologist, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
backgroundIDH1 mutations are causal in tumor development and progression; however, their association with disease characteristics, prognosis, and therapy response in patients with resected intrahepatic cholangiocarcinoma (ICC) remains controversial. MATERIALS AND
methodsIn this cohort study, we recruited 803 patients who underwent curative resection for ICC at a single hospital in China. We performed whole-exome sequencing and Sanger sequencing to identify IDH1 mutations. We used the Kaplan-Meier method and log-rank test to compare overall survival (OS) and disease-free survival (DFS).
resultsA total of 5 different subtypes of IDH1 somatic mutation affecting 94 (11.7%) patients were identified. R132C was the most frequent mutant allele in this cohort, followed by R132L and R132G. Across all patients considered, those that received adjuvant chemotherapy had significantly superior OS and DFS compared with those that did not receive adjuvant chemotherapy. In the whole ICC cohort, patients with IDH1 mutations showed no significant difference in OS compared with patients with wild-type IDH1. When we looked at patients that either received or did not receive adjuvant chemotherapy separately, univariate and multivariable analyses revealed that IDH1 mutations were significantly associated with superior OS among patients that received adjuvant chemotherapy, whereas they were marginally associated with worse OS among patients that did not receive adjuvant chemotherapy.
conclusionWe characterized the distribution of IDH1 mutations in a large cohort of patients with ICC from China. The presence of IDH1 mutations was associated with better survival and decreased risk of recurrence in patients with resected ICC that received adjuvant chemotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.